Octagam (Immune Globulin Intravenous (human)) 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events

August 25, 2010

Audience: Risk Manager, Hematology, Pharmacy

ISSUE: Octapharma USA Inc. initiated a voluntary market withdrawal of selected lots of Octagam [Immune Globulin Intravenous (human)] 5% Liquid Preparation as a result of an increased number of reported thromboembolic events, some of which were serious.

BACKGROUND: There were 9 thromboembolic events potentially associated with 7 of the lots that are being withdrawn from the market. Octagam is indicated for treatment of primary humoral immunodeficiency (PI), such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies.  See FDA Recall Notice for listing of affected lots.

RECOMMENDATION: Customers are asked to immediately quarantine the use of affected lots and to contact Octapharma’s Customer Service Department to arrange for product return.


[08/24/2010 - Recall Notice - FDA]

    

View comments

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web3)